Barclays
OCRX

Barclays’s Ocera Therapeutics, Inc. OCRX Stock Holding History

Barclays’s Portfolio OCRX Stock Details OCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-200
Closed -$1K – 7948
2014
Q2 		$1K Buy
+200
New +$1.59K ﹤0.01% 7548
2014
Q1 		– Sell
-84
Closed -$1K – 7828
2013
Q4 		$1K Buy
+84
New +$785 ﹤0.01% 7478

Other funds holding OCRX

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAAMCP
Pacific Alternative Asset Management Company (PAAMCO) Irvine, California $913M AUM 18.29% 1-Year Est. Return

Barclays's OCRX Position: Q3 2014 in Review

Barclays sold out of Ocera Therapeutics, Inc. (OCRX) in Q3 2014, closing a stake of 200 shares — an estimated $1K sold.

Barclays first reported a position in OCRX in Q4 2013 and held it in 2 quarters. The position peaked at $1K in Q2 2014. 31 funds tracked by Wall St. Rank hold OCRX as of Q3 2014.

  • Barclays reported no remaining Ocera Therapeutics, Inc. position as of Q3 2014 after selling out during the quarter.
  • Barclays sold 200 Ocera Therapeutics, Inc. shares in Q3 2014, an estimated $1K.
  • Barclays first reported a position in Ocera Therapeutics, Inc. in Q4 2013 and held it in 2 quarters.
  • Barclays's Ocera Therapeutics, Inc. position peaked at $1K in Q2 2014.
  • 31 funds tracked by Wall St. Rank held Ocera Therapeutics, Inc. as of Q3 2014.

Based on Barclays's 13F filing for Q3 2014, filed 14 Nov 2014.